Mesa Laboratories 미래 성장

Future 기준 확인 4/6

Mesa Laboratories (는) 각각 연간 134.3% 및 5.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 134.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 27.2% 로 예상됩니다.

주요 정보

134.3%

수익 성장률

134.5%

EPS 성장률

Life Sciences 수익 성장	18.4%
매출 성장률	5.6%
향후 자기자본 수익률	27.2%
애널리스트 커버리지	Low
마지막 업데이트	21 Nov 2024

최근 미래 성장 업데이트

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08

Recent updates

Investors Give Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares A 25% Hiding

Nov 20

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

Oct 17

A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Jul 29

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

May 03

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Mar 15

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

May 31

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Apr 12

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Mar 13

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Dec 20

Mesa Laboratories declares $0.16 dividend

Oct 03

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Sep 09

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

Sep 06

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Aug 08

Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M

Aug 04

Mesa Laboratories declares $0.16 dividend

Jul 07

수익 및 매출 성장 예측

NasdaqGS:MLAB - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2027	263	14	43	53	2
3/31/2026	248	8	41	47	4
3/31/2025	235	10	30	36	4
9/30/2024	228	-246	36	40	N/A
6/30/2024	224	-250	41	45	N/A
3/31/2024	216	-254	42	44	N/A
12/31/2023	213	1	41	44	N/A
9/30/2023	214	-1	36	40	N/A
6/30/2023	219	2	36	41	N/A
3/31/2023	219	1	23	28	N/A
12/31/2022	222	-1	20	25	N/A
9/30/2022	223	-4	28	33	N/A
6/30/2022	200	-2	23	27	N/A
3/31/2022	184	2	35	39	N/A
12/31/2021	163	8	39	43	N/A
9/30/2021	143	5	36	38	N/A
6/30/2021	139	4	42	44	N/A
3/31/2021	134	3	35	37	N/A
12/31/2020	130	-2	31	32	N/A
9/30/2020	128	-2	31	32	N/A
6/30/2020	121	-2	27	29	N/A
3/31/2020	118	2	25	27	N/A
12/31/2019	110	5	27	28	N/A
9/30/2019	105	10	27	28	N/A
6/30/2019	104	8	24	25	N/A
3/31/2019	103	7	29	31	N/A
12/31/2018	104	10	28	30	N/A
9/30/2018	101	-2	27	29	N/A
6/30/2018	99	0	N/A	30	N/A
3/31/2018	96	-3	N/A	26	N/A
12/31/2017	94	-4	N/A	17	N/A
9/30/2017	94	11	N/A	14	N/A
6/30/2017	95	11	N/A	7	N/A
3/31/2017	94	11	N/A	17	N/A
12/31/2016	94	12	N/A	14	N/A
9/30/2016	90	11	N/A	9	N/A
6/30/2016	88	10	N/A	18	N/A
3/31/2016	85	11	N/A	17	N/A
12/31/2015	78	9	N/A	15	N/A
9/30/2015	76	9	N/A	16	N/A
6/30/2015	73	10	N/A	13	N/A
3/31/2015	71	10	N/A	11	N/A
12/31/2014	68	11	N/A	9	N/A
9/30/2014	64	10	N/A	11	N/A
6/30/2014	58	9	N/A	10	N/A
3/31/2014	53	9	N/A	12	N/A
12/31/2013	50	8	N/A	12	N/A

애널리스트 미래 성장 예측

수입 대 저축률: MLAB 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: MLAB (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: MLAB 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: MLAB 의 수익(연간 5.6% ) US 시장( 8.9% 보다 느리게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: MLAB 의 수익(연간 5.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: MLAB 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 27.2 %)

Mesa Laboratories 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 10% to US$130

Consensus EPS estimates upgraded to US$0.055 loss

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Price target decreased by 17% to US$115

Price target decreased by 8.9% to US$139

Consensus EPS estimates increase by 14%

Recent updates

Upcoming dividend of US$0.16 per share

Investors Give Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares A 25% Hiding

Second quarter 2025 earnings: EPS exceeds analyst expectations

CEO, President & Director recently sold US$572k worth of stock

CEO, President & Director notifies of intention to sell stock

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

First quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 16, 2024

Insider notifies of intention to sell stock

Price target increased by 10% to US$130

A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Fourth quarter dividend of US$0.16 announced

Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024

Upcoming dividend of US$0.16 per share

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

Third quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024

Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Consensus EPS estimates upgraded to US$0.055 loss

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024

Insider notifies of intention to sell stock

Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024

Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?

Upcoming dividend of US$0.16 per share at 0.7% yield

Price target decreased by 17% to US$115

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.

Price target decreased by 8.9% to US$139

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?

Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023

CEO, President & Director notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.5% yield

Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt

Now 20% undervalued after recent price drop

Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023

CEO, President & Director exercised options and sold US$166k worth of stock

Consensus EPS estimates increase by 14%

Now 21% undervalued after recent price drop

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

Price target decreased by 11% to US$178

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of US$0.16 per share at 0.4% yield

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.4% yield

VP, CFO & Chief Accounting Officer exercised options and sold US$132k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VP, CFO & Chief Accounting Officer exercised options and sold US$293k worth of stock

Independent Director exercised options and sold US$137k worth of stock